Drugs / Mazdutide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | obesity disorder | — | “NDA for mazdutide 9 mg for weight management in adults was formally submitted in November 2025 and accepted by the National Medical Products Administration (NMPA).” innoventbio.com ↗ “the marketing application for mazdutide 9 mg for long-term weight management in adults with moderate-to-severe obesity was accepted for review” innoventbio.com ↗ |
Trials 39
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT06536023 | Aug 2024 → Jul 2025 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05793450 | May → Sep 2023 | impaired renal function disease | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05815680 | Apr → Aug 2023 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05623839 | Nov 2022 → Jun 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04773977 | Mar 2021 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03928379 | Oct 2019 → Jul 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03325387 | Oct 2017 → Aug 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02972645 | Dec 2016 → Jul 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07000955 | Jun 2025 → Sep 2026 overdue | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06519656 | Oct 2024 → Sep 2026 | polycystic ovary syndrome | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04466904 | Sep 2020 → May 2021 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04440345 | Jun 2020 → Jun 2021 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 27 trials · 2 met primary | ||||||
| Phase 2 | NCT06937749 | Jul 2025 → Apr 2026 overdue | metabolic dysfunction-associated steatohepatitis | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06862908 | Mar 2025 → Sep 2026 overdue | diastolic heart failure, mild heart failure, obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06817356 | Feb 2025 → Mar 2026 | alcohol-related disorders | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06124807 | Nov 2023 → Jan 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT04965506 | Sep 2021 → Apr 2022 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | Met primary |
| Phase 2 | NCT04904913 | Jun 2021 → Mar 2023 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | Met primary |
| Phase 310 trials · 5 met primary | ||||||
| Phase 3 | NCT07469800 | Apr → Aug 2026 overdue | hypertensive disorder, obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07255209 | Dec 2025 → Oct 2027 expected | — | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07083154 | Sep 2025 → Aug 2029 expected | cognitive impairment with or without cerebellar ataxia, dementia, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 3 | NCT06931028 | Jun 2025 → May 2027 expected | obesity disorder, obstructive sleep apnea syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06884293 | May 2025 → Dec 2026 expected | metabolic dysfunction-associated steatotic liver disease, obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06184568 | Feb 2024 → Sep 2025 | obesity disorder, type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | Met primary |
| Phase 3 | NCT06164873 | Dec 2023 → Jun 2025 overdue | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT05606913 | Jan 2023 → Jan 2024 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | Met primary |
| Phase 3 | NCT05628311 | Jan → Oct 2023 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | Met primary |
| Phase 3 | NCT05607680 | Nov 2022 → Aug 2023 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | Met primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT07824895 | Sep 2026 → Dec 2027 expected | gout, metabolic syndrome X, obesity disorder | Hongwei Jiang | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07718126 | Sep 2026 → Feb 2029 expected | metabolic dysfunction-associated steatohepatitis | West China Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07654062 | Jul 2026 → Jun 2028 expected | prediabetes syndrome | Shandong Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07657676 | May 2026 → Oct 2027 expected | coronary atherosclerosis, obesity disorder | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07803705 | Nov 2026 → Jun 2028 expected | obesity disorder, pancreas disorder | Tongji Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07713992 | Sep 2026 → Dec 2027 expected | NAFLD1, type 2 diabetes mellitus | Tianjin Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07797101 | Sep 2026 → May 2029 expected | cirrhosis of liver, fatty liver disease, portal hypertension | The Second Affiliated Hospital of Chongqing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07517042 | Jun 2026 → Dec 2028 expected | obesity disorder | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| — | NCT07633639 | May 2026 → May 2028 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT07135141 | Sep 2025 → Sep 2027 expected | morbid obesity | Beijing Friendship Hospital | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07843862 Comparator | Oct 2026 → Apr 2027 expected | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07417306 Comparator | Mar 2026 → Aug 2027 expected | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 37
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results 2026ADA | Innovent Biologics Presents Results of DREAMS-3: the First Globally Approved GCG/GLP-1 Dual Receptor Agonist versus Semaglutide in a Head-to-Head Phase 3 Randomized Controlled Trial innoventbio.com ↗
Mazdutide 6 mg demonstrated superior efficacy in both glycemic control and weight reduction. |
| 2026-06-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results The Phase 3 GLORY-2 study of mazdutide 9 mg in Chinese adults with moderate to severe obesity was simultaneously published in JAMA and presented at the ADA Scientific Sessions innoventbio.com ↗ |
| 2026-06-06 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Phase 1b Clinical Study Results of Mazdutide in Chinese Adolescents with Obesity Presented as an Oral Report at the American Diabetes Association (ADA) Scientific Sessions innoventbio.com ↗
Results showed that mazdutide 4 mg and 6 mg demonstrated a manageable safety and tolerability profile in Chinese adolescents with obesity. |
| 2026-05-08 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Mazdutide pre-filled multi-dose pen approved by NMPA, bringing new options for long-term treatment of patients with type 2 diabetes innoventbio.com ↗ |
| 2026-03-30 | Innovent Biologics (Suzhou) Co. Ltd. | Results A weight loss of over 15 kg in one year achieved with 9 mg mazdutide in a Phase 2 study of Chinese adults with a BMI ≥ 30 kg/m2; results published in MED, a Cell Press Journal innoventbio.com ↗ |
| 2025-12-18 | Innovent Biologics (Suzhou) Co. Ltd. | Results Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature innoventbio.com ↗
The two Phase 3 studies published in Nature respectively demonstrated the efficacy and safety of mazdutide monotherapy (DREAMS-1, NCT05628311) and add-on therapy to oral anti-diabetic drugs (DREAMS-2, NCT05606913) in Chinese adult participants with T2D. |
| 2025-12-15 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Announces Approval of Mazdutide Injection in Macao, Introducing a Novel Therapeutic Option to Patients with Obesity and Overweight innoventbio.com ↗
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that mazdutide (glucagon [GCG]/glucagon-like peptide-1 [GLP-1] dual receptor agonist) has been approved for marketing by the Pharmaceutical Administration Bureau (ISAF) of the Macao Special Administrative Region of China. |
| 2025-12-12 | Innovent Biologics (Suzhou) Co. Ltd. | Results Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity innoventbio.com ↗
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. |
| 2025-11-25 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population innoventbio.com ↗
the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review |
| 2025-11-20 | Innovent Biologics (Suzhou) Co. Ltd. | Results Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints innoventbio.com ↗
At Week 60, the mazdutide 9 mg group achieved a mean weight reduction of 18.55%, compared to 3.02% in the placebo group. |
| 2025-10-28 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 innoventbio.com ↗
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group |
| 2025-09-19 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes innoventbio.com ↗
Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for glycemic control in adults with T2D. |
| 2025-06-27 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management innoventbio.com ↗
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China’s National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity. |
| 2025-06-25 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions innoventbio.com ↗
Mazdutide demonstrated dual benefits in glycemic control and weight loss, along with comprehensive improvements in cardiovascular, renal, and metabolic indicators. |
| 2025-05-26 | Innovent Biologics (Suzhou) Co. Ltd. | Results Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM) innoventbio.com ↗
This marks the first time that a clinical study of mazdutide, the world’s first dual GCG/GLP-1 receptor agonist submitted for marketing, has been featured in a top-tier, peer-reviewed medical journal. |
| 2024-09-12 | Innovent Biologics (Suzhou) Co. Ltd. | Results Head-to-head Superiority over Dulaglutide: Innovent’s Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 innoventbio.com ↗
The study results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with T2D. |
| 2024-09-02 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024 innoventbio.com ↗
dutide is the first GLP-1R/GCGR dual agonist to successfully complete a Phase 3 study for diabetes, demonstrating superior blood sugar-lowering and weight loss efficacy compared to dulaglutide. |
| 2024-08-01 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China innoventbio.com ↗ |
| 2024-07-22 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA innoventbio.com ↗ |
| 2024-06-25 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA’s 84th Scientific Sessions innoventbio.com ↗
The primary endpoints and all key secondary endpoints of GLORY-1 were met, reconfirming the unique advantages of the GLP-1R/GCGR dual agonist |
| 2024-06-25 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024 innoventbio.com ↗ |
| 2024-05-09 | Innovent Biologics (Suzhou) Co. Ltd. | Results Head-to-head Superiority to High-dose Dulaglutide: Innovent’s First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints innoventbio.com ↗
The study results suggested that mazdutide was superior compared with dulaglutide for glycaemic control, and mazdutide also showed multiple cardiometabolic benefits in T2D patients including weight loss, blood lipid, blood pressure, serum uric acid, liver enzymes, etc. |
| 2024-02-07 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent’s First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China innoventbio.com ↗ |
| 2024-01-09 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA innoventbio.com ↗ |
| 2023-12-18 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications innoventbio.com ↗
Thereby, patients achieved rapid and robust weight loss efficacy and attained multiple cardiovascular and metabolic benefits, including reduced waist circumstance, blood pressure, blood lipids, transaminase as well as reduced serum uric acid. |
| 2023-11-22 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care innoventbio.com ↗ |
| 2023-10-30 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity innoventbio.com ↗
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced the 48-week treatment results of the Phase 2 clinical study (ClinicalTrials.gov, NCT04904913) of higher dose (9 mg) mazdutide (Innovent R&D Code: IBI362) in Chinese subjects with obesity, demonstrating significant weight loss efficacy, favorable safety, and multiple metabolic benefits. |
| 2023-07-12 | Innovent Biologics (Suzhou) Co. Ltd. | Results Preclinical Study Results Show Potential Effect of GLP-1R/GCGR Dual Agonist Mazdutide (IBI362) in Reducing Serum Uric Acid Levels innoventbio.com ↗
The results of the study showed that mazdutide statistically significantly reduced serum uric acid levels compared to semaglutide in the hyperuricemia model. |
| 2023-05-11 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint innoventbio.com ↗
The results showed that mazdutide 9 mg demonstrated superior body weight loss versus placebo in Chinese subjects with obesity. |
| 2022-10-17 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine innoventbio.com ↗
The results of the higher-dose mazdutide make it the first single-agent anti-obesity drug worldwide to achieve a 12-week body weight loss by more than 11.5%. |
| 2022-07-19 | Innovent Biologics (Suzhou) Co. Ltd. | Results Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint innoventbio.com ↗
All doses of mazdutide significantly reduced HbA1c levels, compared with placebo (p < 0.0001 for all comparisons versus placebo). |
| 2022-06-29 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications innoventbio.com ↗
IBI362 was well tolerated and showed multiple benefits of blood glucose control, weight loss and metabolic profiles. |
| 2022-06-13 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362）in Chinese Adults with Overweight or Obesity at ENDO 2022 innoventbio.com ↗
Results of cohort 4 and 5 (high-dose) were firstly presented at ENDO 2022. |
| 2022-06-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints innoventbio.com ↗
Mazdutide demonstrated superior weight loss efficacy in Chinese participants with overweight or obesity compared with placebo in a dose-dependent manner. |
| 2021-12-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021 innoventbio.com ↗
At week 12, mean changes from baseline in HbA1c levels were −1.46%, −2.23% and −1.66% for patients receiving IBI362 in cohort 1,2 and 3, respectively (−1.98% for dulaglutide). |
| 2021-08-18 | Innovent Biologics (Suzhou) Co. Ltd. | Results Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet innoventbio.com ↗
SAN FRANCISCO, U.S. and SUZHOU, China, August 17, 2021— Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that phase 1b study results of IBI362, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese participants with overweight or obesity have been published in EClinicalMedicine by the Lancet. |
| 2021-06-25 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association’s 81st Scientific Sessions innoventbio.com ↗
IBI362 was well tolerated and showed a favorable safety profile. |
All press releases naming this drug 51 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 43 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mazdutide | “Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 2022 |
| Known as | IBI362 | “Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 202220“Mazdutide (IBI362) is a GLP-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist.” NCT07654062 ↗ |
| Known as | LY3305677 | “We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) to evaluate the safety and efficacy of IBI362 (LY3305677), a GLP-1 and glucagon...” PMID 35750681 ↗ Jun 20226“Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 2022 |
| Known as | Mazdutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095358 ↗ |
| Action | Activate | “glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist” PMID 36247927 ↗ Oct 2022 |
| Modality | Protein / enzyme biologic | — CHEMBL5095358 ↗ |
| Route | Subcutaneous | “Single escalating doses of LY3305677 administered subcutaneously (SC)” NCT02972645 ↗ |
| Target | GCGR | “GLP-1R and GCGR dual agonist” NCT06519656 ↗ |